MétaCan
Menu
← Back to cohort
Record W7116974781 · doi:10.1002/alz70861_108827

Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes

2025· article· en· W7116974781 on OpenAlexaff
Susan Abushakra, P. Murali Doraiswamy, Earvin Liang, Duygu Tosun, Marwan N. Sabbagh, Anton P. Porsteinsson, David Watson, Aidan Power, Sharon Cohen, Emer MacSweeney, John A. Hey, Susan Flint, Patrick Kesslak, Luc Bracoud, Chris J. Conklin, Adem Albayrak, Margaret Bray, Martin Tolar

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsToronto Public Health
Fundersnot available
KeywordsNeurodegenerationHippocampal formationSubgroup analysisClinical trialHippocampusAmyloid βAmyloid (mycology)NeuroprotectionNeuroplasticity

Abstract

fetched live from OpenAlex

BACKGROUND: Valiltramiprosate (ALZ-801), an oral inhibitor of amyloid oligomer formation, was evaluated in a Phase 3 trial in APOE4/4 homozygotes with Early AD (Abushakra, 2024); the topline results being presented at this meeting (Power, 2025). While the primary clinical endpoint was not significant, hippocampal volume (HV, main imaging outcome) showed significant slowing of atrophy. METHOD: This 78-week placebo-controlled study randomized 325 homozygotes (placebo, 265 mg BID), stratified by MCI/Mild AD. ADAS-Cog13 and CDR-SB were the primary and key secondary outcomes respectively, and DAD (disability assessment for dementia) was a secondary outcome. HV was the main imaging outcome, cortical thickness and whole brain volume (CT, WBV) were secondary. Analyses by disease stage were pre-specified using baseline severity as covariate in the MMRM model; drug-effect correlations utilized Spearman's correlations. RESULT: The pre-specified MCI subgroup (MMSE 27-30) included 125 subjects (58 placebo, 67 active); with balanced baseline characteristics except for cholinesterase-inhibitors (placebo 31%, active 19%). Imaging population included 54 placebo, 62 active subjects. The MCI subgroup vs placebo showed positive effects on ADAS-cog/DAD (nominal p <0.05), trend on CDR-SB (p =0.053) with significant slowing of HV, CT and WBV atrophy vs placebo (26%, p =0.004; 35% p < 0.0001; 22%, p =0.027). In the active arm, change in HV correlated significantly with change in ADAS-Cog13 (r=-0.40, p <0.005), CDR-SB (r=-0.45, p <0.005), and DAD (r=0.33, p =0.018). For CT, the correlations were also significant: ADAS-Cog13 (r=-0.34, p =0.015), CDR-SB (r=-0.49, p < 0.005), and DAD (r=0.40, p <0.005). WBV treatment effect also correlated with the clinical outcomes (p ≤ 0.01). CONCLUSION: These strong correlations between structural preservation and clinical benefits of valiltramiprosate at the MCI stage support its efficacy and are consistent with its proposed mechanism of inhibiting amyloid oligomer formation, thereby potentially protecting neurons from synaptic dysfunction and neurodegeneration. Given the accelerated neurodegeneration in APOE4/4 patients, these findings suggest that intervention at the early stages of AD when neuronal reserve is higher, may be critical for valiltramiprosate to exert meaningful clinical effects alongside preservation of brain structure and volume.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.364
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→